Analyst
TD Cowan
Equibles does not estimate personal net worth.
Steve Scala is recorded as Analyst at TD Cowan. Steve Scala has spoken on 6 earnings calls across 5 companies, most recently for Pfizer Inc on November 3, 2026. Those appearances were for Pfizer Inc (PFE), ELI LILLY & Co (LLY), Novartis AG (NVS), Merck & Co., Inc. (MRK) and AbbVie Inc. (ABBV). The companies whose calls Steve Scala spoke on are classified in the Healthcare sector.
“Given the push out of MEVPRO 1, were there any changes to MEVPRO 2 and 3 timelines? So that's the first question. Second question is for Cecile.”
“This is a follow-up to Chris's earlier question. And with all due respect, Lilly's financial guidance hasn't been a good predictor on ultimate results. And I'm curious, what is the most frequent source of this surprise?”
“On the second quarter call, Novartis said that Inalumab was on track for a Q3 approval. So we're now a third of the way through Q4 and no news.”
“First, on Tilrecomeg, can you confirm that the trial versus Dupixent will be a true head-to-head trial powered for superiority on first line or in-first-line bio-naive patients.”
“What are the gating factors for FDA acceptance of the in-linked application. And Dean, can you speak to the changes that you're pursuing on titration? What shorter durations are you pursuing?”
TD Cowan
Analyst
Transcript header (unverified)
PFE
Drug Manufacturers - General · Healthcare
LLY
Drug Manufacturers - General · Healthcare
NVS
Drug Manufacturers - General · Healthcare
Drug Manufacturers - General · Healthcare
ABBV
Drug Manufacturers - General · Healthcare
